Trial provides first look at long-term outcomes of childhood immunotherapies

By reprogramming a patient’s own immune cells to recognize and destroy cancer, chimeric antigen receptor (CAR) T cells have significantly improved survival for children with refractory or relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, decades of research and care have shown that treatment for pediatric cancers can affect survivors long into adulthood. So, learning from the past, a national group of physicians and scientists developing CAR T–cell therapies (the CARnation Consortium) decided to take an active approach to detecting any long-term side effects associated with these novel therapeutic agents. 

Read more: https://www.stjude.org/research/progress/2026/trial-provides-first-look-at-long-term-outcomes-of-childhood-imm.html